According to The Insight Partners' research, the Asia Pacific Vaccines Market was valued at US$ 15,065.1 Million in 2024 and is expected to reach US$ 22,940.5 Million by 2031, registering a CAGR of 6.2% from 2025 to 2031.
Surging immunization programs, government initiatives, and development of combination and therapeutic vaccines are among the critical factors attributed to drive the Asia Pacific vaccines market growth.
Immunization programs offer services that ensure immunity to vaccine-preventable diseases. These services include documenting evidence of immunity, administering immunizations and re-immunizations, and maintaining records for reporting to state or local immunization information systems (IIS), also known as vaccine registries.
The Essential Programme for Immunization (EPI), developed by WHO, was designed to coordinate the targeted implementation of vaccination through national immunization programs. This initiative has been instrumental in expanding global vaccine access. Additionally, the establishment of Gavi, the Vaccine Alliance, an independent multilateral funding mechanism in 2000, aimed at increasing global access to vaccines, has played a critical role in facilitating vaccine introduction in low- and middle-income countries (LMICs). According to an article published in the Journal of Infectious Diseases in October 2021, it is estimated that vaccine access has prevented at least 37 million deaths in 98 LMICs by protecting against 10 vaccine-preventable diseases, including Haemophilus influenzae type B, Japanese encephalitis, Neisseria meningitidis serogroup A, measles, Streptococcus pneumoniae, rotavirus, rubella, and yellow fever.
The World Health Assembly, with the support of various countries and partners, launched a strategy called the Immunization Agenda 2030 in 2020. This initiative aims to address vaccination challenges and save over 50 million lives by 2030. For example, India's immunization program is one of the largest public health initiatives in the world. It was initially launched as the Expanded Program on Immunization in 1978 and was renamed the Universal Immunization Program (UIP) in 1985, expanding its reach beyond urban areas. The program provides free vaccines against 12 vaccine-preventable diseases to over 27 million newborns and 30 million pregnant women annually. In 2014, Mission Indradhanush was launched by the Government of India, with a focused aim to target unvaccinated and partially vaccinated children, as well as pregnant women in high-risk and hard-to-reach areas, with the goal of achieving 90% full immunization coverage. As of 2022, more than 44.5 million children and 11.2 million pregnant women have been vaccinated under this initiative.
On the contrary, high vaccine development cost and increased time to market hampers the growth of the Asia Pacific vaccines market.
Asia Pacific Vaccines Market Segmentation Analysis:
- By Type, the Asia Pacific Vaccines Market is segmented into Conjugated Vaccines, Inactivated Vaccines, Live Vaccines, Recombinant Vaccines, and Toxoid Vaccines. The Conjugated segment is projected to expand at a CAGR of 6.9% during 2025 - 2031.
- By Indication, the Asia Pacific Vaccines Market is segmented into HPV, PCV, DTP, Hepatitis, Influenza, Dengue, and Other. The HPV segment is projected to expand at a CAGR of 7.9% during 2025 - 2031.
- By Route of Administration, the Asia Pacific Vaccines Market is segmented into Injection, Oral, and Other. The Injection segment is projected to expand at a CAGR of 6.0% during 2025 - 2031.
- By Age Group, the Asia Pacific Vaccines Market is segmented into Pediatric and Adult. The Pediatric segment is projected to expand at a CAGR of 6.4% during 2025 - 2031.
By country, the Asia Pacific Vaccines Market is categorized into China, Japan, India, Australia, South Korea, Rest of APAC. China is projected to expand at a CAGR of 6.5% during 2025 - 2031.
Key players operating in the Vaccines Market are Abbott Laboratories, GSK Plc, Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi SA, CSL Ltd, Serum Institute of India Pvt Ltd, BioNTech SE, and Sinovac Biotech Ltd., among others.
- In July 2022, SINOVAC, along with the HKU-CTC research team and Gleneagles Hospital Hong Kong, has started a clinical trial for an Omicron-specific inactivated vaccine as a booster in healthy adults. A ceremony was held at Gleneagles to mark the beginning of the study, which aims to evaluate the vaccine's safety and immune response, contributing to future vaccination strategies.
- In May 2024, the Serum Institute of India (SII) shipped its first batch of the R21 malaria vaccine to Africa. So far, SII has produced 25 million doses of this vaccine. The development of the R21/Matrix-M vaccine took 30 years of research.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com